Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML) is an aggressive disease with limited options for treatment. Here, the authors utilize DNA methylation based subgroups in JMML to predict clinical outcome.
Guardado en:
Autores principales: | Elliot Stieglitz, Tali Mazor, Adam B. Olshen, Huimin Geng, Laura C. Gelston, Jon Akutagawa, Daniel B. Lipka, Christoph Plass, Christian Flotho, Farid F. Chehab, Benjamin S. Braun, Joseph F. Costello, Mignon L. Loh |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/722c1dde424443b9b6f04f8e32625fea |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
por: Daniel B. Lipka, et al.
Publicado: (2017) -
JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
por: Yunus Murat Akcabelen, et al.
Publicado: (2021) -
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
por: Mattias Hofmans, et al.
Publicado: (2021) -
Systemic mastocytosis associated with chronic myelomonocytic leukemia and xanthogranuloma
por: Philipp Tschandl, et al.
Publicado: (2012) -
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
por: Ryan M. Carr, et al.
Publicado: (2021)